Clinical Trials
15
Active:2
Completed:8
Trial Phases
5 Phases
Phase 1:5
Phase 2:2
Phase 3:2
+2 more phases
Drug Approvals
4
CANADA:2
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (45.5%)Phase 2
2 (18.2%)Phase 3
2 (18.2%)Not Applicable
1 (9.1%)Phase 4
1 (9.1%)A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Phase 3
Recruiting
- Conditions
- Uterine FibroidsEndometriosis
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 1000
- Registration Number
- NCT05862272
- Locations
- 🇺🇸
Mobile, Mobile, Alabama, United States
🇺🇸Chandler, Chandler, Arizona, United States
🇺🇸Mesa, Mesa, Arizona, United States
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
Recruiting
- Conditions
- Pregnancy, High RiskPregnancy ComplicationsPregnancy Related
- Interventions
- Drug: Relugolix-Containing Product
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 728
- Registration Number
- NCT05739123
- Locations
- 🇺🇸
PPD, Wilmington, North Carolina, United States
MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy
Active, not recruiting
- Conditions
- Pregnancy RelatedPregnancy ComplicationsPregnancy, High Risk
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 530
- Registration Number
- NCT05739136
- Locations
- 🇺🇸
SMPA, Marlborough, Massachusetts, United States
Congenital Athymia Patient Registry
Recruiting
- Conditions
- Congenital AthymiaComplete DiGeorge SyndromeComplete DiGeorge Anomaly
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 75
- Registration Number
- NCT05329935
- Locations
- 🇺🇸
Duke University School of Medicine, Durham, North Carolina, United States
Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
Phase 3
Active, not recruiting
- Conditions
- Contraception
- Interventions
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Sumitomo Pharma Switzerland GmbH
- Target Recruit Count
- 1020
- Registration Number
- NCT04756037
- Locations
- 🇺🇸
Mobile, Mobile, Alabama, United States
🇺🇸Chandler, Chandler, Arizona, United States
🇺🇸Mesa, Mesa, Arizona, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found